{"id":"tocilizumab-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking interleukin-6, tocilizumab reduces inflammation and has anti-inflammatory effects. This mechanism is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.","oneSentence":"Tocilizumab Injection is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:11.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT07477795","phase":"PHASE2","title":"Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Takayasu Arteritis, Large Vessel Vasculitis","enrollment":52},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT05233397","phase":"PHASE2","title":"ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-12-16","conditions":"Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma","enrollment":38},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT04246086","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-12","conditions":"Follicular Lymphoma","enrollment":237},{"nctId":"NCT04634552","phase":"PHASE2","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hematological Malignancies","enrollment":510},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06934044","phase":"PHASE1","title":"A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-13","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT05835986","phase":"PHASE1","title":"A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-18","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT03999749","phase":"PHASE2","title":"A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-06-11","conditions":"Melanoma","enrollment":71},{"nctId":"NCT07459335","phase":"","title":"TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients","status":"COMPLETED","sponsor":"Groupe français d'étude des Maladies Inflammatoires de loeil","startDate":"2012-01-01","conditions":"Giant Cell Arteritis (GCA), Cardiovascular Diseases","enrollment":1667},{"nctId":"NCT05583617","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-14","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT05927571","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-08-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":120},{"nctId":"NCT03075696","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-02-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":940},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":"Systemic Sclerosis","enrollment":92},{"nctId":"NCT05207670","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-02-01","conditions":"Non-Hodgkin Lymphoma","enrollment":320},{"nctId":"NCT07115745","phase":"PHASE1","title":"A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-09-04","conditions":"Refractory Autoimmune Diseases","enrollment":125},{"nctId":"NCT06624085","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-28","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT06863480","phase":"PHASE1","title":"Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03-02","conditions":"Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia","enrollment":30},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT05091424","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":137},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT07108387","phase":"PHASE2","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-11","conditions":"Giant Cell Arteritis (GCA)","enrollment":78},{"nctId":"NCT03448042","phase":"PHASE1","title":"A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2018-06-06","conditions":"Solid Tumors","enrollment":123},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT03970226","phase":"EARLY_PHASE1","title":"Tocilizumab in Children With ACP","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-09-16","conditions":"Adamantinomatous Craniopharyngioma","enrollment":9},{"nctId":"NCT07392814","phase":"PHASE1","title":"Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-10","conditions":"Leukemia Acute Myeloid - AML","enrollment":12},{"nctId":"NCT05646836","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-03-21","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05391750","phase":"PHASE1","title":"Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":7},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07006532","phase":"NA","title":"Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-01-01","conditions":"Kidney Transplant Rejection","enrollment":50},{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT05609630","phase":"PHASE3","title":"Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-10-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":90},{"nctId":"NCT04088396","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-02-12","conditions":"Systemic Juvenile Idiopathic Arthritis","enrollment":58},{"nctId":"NCT05535244","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-17","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT04375228","phase":"PHASE2","title":"Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2020-09-25","conditions":"Immune-related Adverse Events, Advanced Solid Tumor","enrollment":8},{"nctId":"NCT05734690","phase":"PHASE4","title":"COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-05-05","conditions":"Heart Failure","enrollment":503},{"nctId":"NCT03275103","phase":"PHASE1","title":"Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-09-19","conditions":"Multiple Myeloma","enrollment":355},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT04712097","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-27","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":478},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT07377058","phase":"NA","title":"RCT of Tocilizumab for Anti-MDA5+DM","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-11-01","conditions":"Dermatomyositis","enrollment":110},{"nctId":"NCT06492837","phase":"PHASE2","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-10-23","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT05070247","phase":"PHASE1, PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma","enrollment":61},{"nctId":"NCT05846789","phase":"PHASE2","title":"SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers","status":"RECRUITING","sponsor":"Kathy Miller","startDate":"2024-07-02","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer","enrollment":168},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT01782235","phase":"PHASE2, PHASE3","title":"Efficacy of Tocilizumab in Primary Sjögren's Syndrome.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2013-07-24","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":110},{"nctId":"NCT07254637","phase":"PHASE2","title":"Tocilizumab in Chronic Inflammatory CPPD Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Calcium Pyrophosphate Deposition Disease","enrollment":80},{"nctId":"NCT05869955","phase":"PHASE1","title":"A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2023-09-13","conditions":"Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis","enrollment":270},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT06037460","phase":"PHASE3","title":"TocilizuMab discontinuAtion in GIant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-05-13","conditions":"Giant Cell Arteritis","enrollment":120},{"nctId":"NCT06452537","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-09","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","enrollment":102},{"nctId":"NCT06043674","phase":"PHASE2","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2024-01-22","conditions":"Chronic Lymphocytic Leukemia, Richter's Transformation","enrollment":70},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04691817","phase":"PHASE1, PHASE2","title":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-07-25","conditions":"Lung Cancer, Nonsmall Cell","enrollment":28},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT04395222","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-07","conditions":"Hematologic Malignancy, Bone Marrow Transplant","enrollment":21},{"nctId":"NCT03533283","phase":"PHASE1, PHASE2","title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-08","conditions":"Non-Hodgkins Lymphoma","enrollment":211},{"nctId":"NCT04779957","phase":"PHASE2","title":"Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2021-10-01","conditions":"Kidney Transplantation, Graft Failure","enrollment":18},{"nctId":"NCT07281027","phase":"PHASE3","title":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03-01","conditions":"New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)","enrollment":438},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT07263776","phase":"PHASE3","title":"Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-12-05","conditions":"Acute Ischemic Stroke","enrollment":692},{"nctId":"NCT06251076","phase":"PHASE4","title":"Plan Development for Giving Teclistamab in the Outpatient Setting","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-11-19","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Cancer","enrollment":15},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT03564340","phase":"PHASE1, PHASE2","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-05-21","conditions":"Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer","enrollment":890},{"nctId":"NCT05364424","phase":"PHASE1","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-11-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":43},{"nctId":"NCT03892785","phase":"PHASE3","title":"MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Giant Cell Arteritis","enrollment":230},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT03787290","phase":"PHASE2","title":"Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder","status":"SUSPENDED","sponsor":"Massachusetts General Hospital","startDate":"2026-12-01","conditions":"Major Depressive Disorder","enrollment":35},{"nctId":"NCT06262477","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-01-02","conditions":"Healthy Volunteer","enrollment":300},{"nctId":"NCT06721910","phase":"NA","title":"Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-15","conditions":"Healthy, Glucagon Resistance, Amino Acid Change","enrollment":26},{"nctId":"NCT01791842","phase":"PHASE2","title":"TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05-05","conditions":"Fibrous Dysplasia of Bone","enrollment":19},{"nctId":"NCT02929251","phase":"PHASE2","title":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-29","conditions":"Uveitis, Biotherapy","enrollment":112},{"nctId":"NCT01673919","phase":"PHASE3","title":"A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":7},{"nctId":"NCT05237232","phase":"","title":"Modeling of Intracerebral Vascularization After Extracorporeal Membrane Oxygenation in Children","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-31","conditions":"Extra Corporeal Membrane Oxygenation, Decanulated Alive","enrollment":30},{"nctId":"NCT01394276","phase":"","title":"An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT06247722","phase":"","title":"Real World Use of Tocilizumab Biosimilar studY","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2024-03-05","conditions":"Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ANURIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"},{"count":1,"reaction":"THERAPY CESSATION"}],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ROACTEMRA","Actemra","ACTEMRA®"],"phase":"phase_3","status":"active","brandName":"Tocilizumab Injection","genericName":"Tocilizumab Injection","companyName":"Abderrahmane Mami Hospital","companyId":"abderrahmane-mami-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab Injection is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}